Double-blind placebo-controlled trial of ketazolam in anxiety

C. L. Bowden

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Ketazolam, a new, long-acting benzodiazepine, was compared to placebo in a four-week double-blind study in 77 psychiatric outpatients with moderate to severe anxiety. The average optimum dose of ketazolam was 58.6 mg (range, 25 to 125 mg) given in a single bedtime dose. Fifteen patients in the placebo group (41%) dropped out of the study, 12 because of ineffectiveness of the medication and 3 because of intolerable side effects. In the ketazolam group, 5 patients (13%) dropped out because of ineffectiveness of the medication. This difference between treatment groups was statistically significant. Ketazolam was significantly more effective than placebo in reducing symptomatology on 10 of 14 Hamilton Anxiety Rating Scale categories and total scores, the Physician's and Patient's Global Impressions, and the Patient's Self-Rating Symptom Scales. The average number of side effects per patient receiving ketazolam was less at every evaluation period than for patients receiving placebo.

Original languageEnglish (US)
Pages (from-to)170-178
Number of pages9
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume24
Issue number2
StatePublished - 1978

Fingerprint

Anxiety
Placebos
Benzodiazepines
Double-Blind Method
Psychiatry
ketazolam
Outpatients
Physicians
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Double-blind placebo-controlled trial of ketazolam in anxiety. / Bowden, C. L.

In: Current Therapeutic Research - Clinical and Experimental, Vol. 24, No. 2, 1978, p. 170-178.

Research output: Contribution to journalArticle

@article{6b16cdf69da94ed5af85f0c918af2be5,
title = "Double-blind placebo-controlled trial of ketazolam in anxiety",
abstract = "Ketazolam, a new, long-acting benzodiazepine, was compared to placebo in a four-week double-blind study in 77 psychiatric outpatients with moderate to severe anxiety. The average optimum dose of ketazolam was 58.6 mg (range, 25 to 125 mg) given in a single bedtime dose. Fifteen patients in the placebo group (41{\%}) dropped out of the study, 12 because of ineffectiveness of the medication and 3 because of intolerable side effects. In the ketazolam group, 5 patients (13{\%}) dropped out because of ineffectiveness of the medication. This difference between treatment groups was statistically significant. Ketazolam was significantly more effective than placebo in reducing symptomatology on 10 of 14 Hamilton Anxiety Rating Scale categories and total scores, the Physician's and Patient's Global Impressions, and the Patient's Self-Rating Symptom Scales. The average number of side effects per patient receiving ketazolam was less at every evaluation period than for patients receiving placebo.",
author = "Bowden, {C. L.}",
year = "1978",
language = "English (US)",
volume = "24",
pages = "170--178",
journal = "Current Therapeutic Research",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "2",

}

TY - JOUR

T1 - Double-blind placebo-controlled trial of ketazolam in anxiety

AU - Bowden, C. L.

PY - 1978

Y1 - 1978

N2 - Ketazolam, a new, long-acting benzodiazepine, was compared to placebo in a four-week double-blind study in 77 psychiatric outpatients with moderate to severe anxiety. The average optimum dose of ketazolam was 58.6 mg (range, 25 to 125 mg) given in a single bedtime dose. Fifteen patients in the placebo group (41%) dropped out of the study, 12 because of ineffectiveness of the medication and 3 because of intolerable side effects. In the ketazolam group, 5 patients (13%) dropped out because of ineffectiveness of the medication. This difference between treatment groups was statistically significant. Ketazolam was significantly more effective than placebo in reducing symptomatology on 10 of 14 Hamilton Anxiety Rating Scale categories and total scores, the Physician's and Patient's Global Impressions, and the Patient's Self-Rating Symptom Scales. The average number of side effects per patient receiving ketazolam was less at every evaluation period than for patients receiving placebo.

AB - Ketazolam, a new, long-acting benzodiazepine, was compared to placebo in a four-week double-blind study in 77 psychiatric outpatients with moderate to severe anxiety. The average optimum dose of ketazolam was 58.6 mg (range, 25 to 125 mg) given in a single bedtime dose. Fifteen patients in the placebo group (41%) dropped out of the study, 12 because of ineffectiveness of the medication and 3 because of intolerable side effects. In the ketazolam group, 5 patients (13%) dropped out because of ineffectiveness of the medication. This difference between treatment groups was statistically significant. Ketazolam was significantly more effective than placebo in reducing symptomatology on 10 of 14 Hamilton Anxiety Rating Scale categories and total scores, the Physician's and Patient's Global Impressions, and the Patient's Self-Rating Symptom Scales. The average number of side effects per patient receiving ketazolam was less at every evaluation period than for patients receiving placebo.

UR - http://www.scopus.com/inward/record.url?scp=0018235659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018235659&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0018235659

VL - 24

SP - 170

EP - 178

JO - Current Therapeutic Research

JF - Current Therapeutic Research

SN - 0011-393X

IS - 2

ER -